

Manuscript title

Engineering Highly Thermostable Cas12b via De Novo Structural Analyses for One-Pot Detection of Nucleic Acids

Long T. Nguyen^{1,†}, Santosh R. Rananaware^{1,†}, Lilia G. Yang^{1,†}, Nicolas C. Macaluso^{1,†,††}, Julio E. Ocana-Ortiz², Katelyn S. Meister¹, Brianna L.M. Pizzano³, Luke Samuel W. Sandoval⁴, Raymond C. Hautamaki⁵, Zoe R. Fang⁵, Sara M. Joseph¹, Grace M. Shoemaker¹, Dylan R. Carman¹, Liwei Chang⁶, Noah R. Rakestraw⁷, Jon F. Zachary⁷, Sebastian Guerra⁸, Alberto Perez⁶, Piyush K. Jain^{1,9,10,*}

¹Department of Chemical Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville FL, USA

²Department of Chemical Engineering, University of Puerto Rico - Mayagüez, Puerto Rico, USA

³Department of Agricultural and Biological Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville FL, USA

⁴Department of Biology, College of Liberal Arts and Sciences, University of Florida, Gainesville, Florida, USA

⁵Department of Microbiology and Cell Science, College of Agricultural and Life Sciences, University of Florida, Gainesville, Florida, USA

⁶Department of Chemistry, College of Liberal Arts and Sciences, University of Florida, Gainesville, Florida, USA

⁷Department of Graduate Education, College of Medicine, University of Florida, Gainesville, Florida, USA

⁸Genetics Institute, College of Medicine, University of Florida, Gainesville, Florida, USA

⁹Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida, USA

¹⁰UF Health Cancer Center, University of Florida, Gainesville FL, USA

[†]These authors contributed equally

* Corresponding Author and Lead Contact: Jainp@ufl.edu

^{††}Present Address: Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA

SUMMARY

CRISPR/Cas-based diagnostics have the potential to elevate nucleic acid detection. CRISPR/Cas systems can be combined with a pre-amplification step in a one-pot reaction to simplify the workflow and reduce carryover contamination. Here, we report an engineered Cas12b with improved thermostability that falls within the optimal temperature range (60-65°C) of reverse transcription-loop-mediated isothermal amplification (RT-LAMP). Using *de novo* structural analyses, we introduce mutations to wild-type BrCas12b to tighten its hydrophobic cores, thereby enhancing thermostability. The one-pot detection assay utilizing the engineered BrCas12b, coined SPLENDID (Single-pot LAMP-mediated engineered BrCas12b for nucleic acid detection of infectious diseases), exhibits robust trans-cleavage activity up to 67°C in a one-pot setting. We validate SPLENDID clinically in 80 hepatitis C serum samples and 66 SARS-CoV-2 saliva samples with high specificity and accuracy. We obtain results in as little as 20 minutes, and with the extraction process, the entire assay can be performed within an hour.

KEYWORDS

CRISPR, Cas12b, Protein engineering, Thermal stability, Diagnostics, Hepatitis C, Point-of-care diagnostics, Trans-cleavage, RT-LAMP, One-pot detection.

INTRODUCTION

Since the beginning of the COVID-19 pandemic, CRISPR-based diagnostic platforms have become a prominent detection technology that could identify the emergence of future pathogens via massive surveillance testing and potentially replace the traditional time-consuming reverse transcription - quantitative polymerase chain reaction (RT-qPCR) method¹⁻⁵. Recent advancements in CRISPR-based tests

allow for the combination of a pre-amplification step, such as reverse transcription loop-mediated isothermal amplification (RT-LAMP), and a CRISPR reaction into a convenient one-pot detection assay⁶. RT-LAMP is a highly sensitive reaction that can result in detectable signals in as fast as 5-10 minutes⁷. However, since the optimal temperature for the RT-LAMP reaction is around 60°C-65°C⁷⁻⁹, coupling it with CRISPR-Cas systems has been less effective due to the lack of Cas thermostability in this range. Recently reported STOPCovid technology employed a thermostable Cas12b from *Alicyclobacillus acidiphilus* (AapCas12b), but one drawback of the system is that the Cas effector ceases to display enzymatic activity at temperatures higher than 60°C⁶. In our previous study, we implemented a thermostable Cas12b, which is derived from *Brevibacillus sp.* SYP-B805 (BrCas12b) and exhibited high enzymatic activity up to 63.4°C within a single-pot CRISPR-Cas diagnostic assay for detection of nucleic acids. Our one-pot assay successfully distinguished multiple SARS-CoV-2 Variants of Concerns (VOCs) with high sensitivity and specificity within 20 minutes¹⁰. However, while BrCas12b allowed for detection at a higher temperature than AapCas12b, the range of detection was still narrow. RT-LAMP primers are substantially dependent on temperature due to their loop-forming nature. Consequently, single-degree changes often result in significant improvement to target amplification, sensitivity, and specificity^{7,11}.

To allow for enzymatic activity at high temperatures such that complete coverage of the optimal range of RT-LAMP could be attained, we employed *de novo* structural analyses to engineer a more thermostable BrCas12b for better flexibility within the use of the one-pot assay. We employed the capabilities of AlphaFold and SWISS-MODEL to obtain predicted structures of wild-type BrCas12b for the visualization of amino acid interaction¹²⁻¹⁷. These structures were inputted into the

stability prediction tools HotSpotWizard and DeepDDG, which helped us gain insight into potential mutations that encourage thermostability^{18,19}. These tools have been particularly useful for determination of hotspots and predicted $\Delta\Delta G$ to aid in protein engineering for enhanced stability, catalytic activity, and specificity. For instance, an engineered version of xylanase from *Gloeophyllum trabeum* was demonstrated by Wang et al. to have an improved temperature optimum up to 80°C and enhanced stability at low pH (2 - 7.5) compared to the wild-type enzyme, enabling applications in feed and brewing industries²⁰. In another study, mutations D52N and S129A were introduced into pepsin based on $\Delta\Delta G$ calculations, and the half-life of these mutants was increased significantly²¹. However, so far there have been no reports on improving the thermostability of Cas effectors for diagnostic purposes.

Here, we report engineered BrCas12b variants (eBrCas12b) that show up to a 13-fold increase in activity and melting temperatures of 10°C higher than AapCas12b and 6°C higher than wild-type BrCas12b. When combined in a one-pot reaction with RT-LAMP, the engineered BrCas12b with the highest thermostability was observed to have robust detection capability up to 67°C. Since RT-LAMP is typically performed between 60-65°C, the engineered BrCas12b variant enabled the combination of the RT-LAMP and CRISPR trans-cleavage assays to be carried out at a higher temperature range, allowing for more versatility and ease of primer design. The one-pot assay, which we coined SPLENDID (Single-pot LAMP-mediated engineered BrCas12b for nucleic acid detection of infectious diseases), can be performed in low-resource areas and offers robust sensitivity and specificity in as little as 20 minutes.

RESULTS

Identification of stabilizing mutants of BrCas12b

Type V and VI CRISPR-Cas systems such as Cas12a, Cas12b, and Cas13a-d have been harnessed for detection of nucleic acids^{1,22-25}. While Cas12a and Cas13a have been extensively deployed for on-site applications, Cas12b has recently emerged as a distinct class of enzyme, the majority of which are thermostable²⁶⁻²⁸. Unlike Cas12a, Cas12b requires both a crRNA and tracrRNA to carry out cleavage of double-stranded DNA (dsDNA) and subsequent collateral cleavage of single-stranded DNA (ssDNA) (referred to as trans-cleavage activity) (Figure 1A)^{26,28,29}. Although CRISPR-Cas systems can detect nucleic acids, they suffer from a low sensitivity that lies within the picomolar range^{23,30}. Traditionally, CRISPR-based detection platforms are coupled with a pre-amplification step to increase the sensitivity of detection^{1-3,22}. Amplification-free methods have also been developed and successfully executed^{31,32}. However, they require multiple guide RNAs to have detectable signal readouts, and as a result, it can be challenging for these assays to distinguish subvariants for genotyping purposes.

Reverse transcription - loop-mediated isothermal amplification (RT-LAMP) has emerged as a powerful tool for molecular diagnostics due to its rapid isothermal amplification in as quick as 5-10 minutes⁷. Since four to six primers are needed to achieve such high sensitivity, false positives resulting from primer-dimer formation are a major limitation of this technology^{33,34}. Recent efforts have coupled RT-LAMP with a thermostable CRISPR-Cas complex in a one-pot reaction to overcome this drawback⁶. The programmability of the CRISPR-Cas systems improves the specificity of detection. Upon amplification, correct base-pairing between the guide RNA and the amplified target serves as an additional checkpoint to provide accurate signal readouts. The one-pot reaction further eliminates carryover contamination that is frequently observed with two-pot RT-LAMP-coupled platforms¹⁰. Most RT-LAMP reactions work optimally

between 60°C - 65°C^{7,11}; however, only a handful of Cas enzymes are functional at this temperature range^{6,35}. The discrepancies in reaction conditions and inhibitory effects between amplification and trans-cleavage have been major hurdles in developing such one-pot systems. Recently, we reported the use of a thermostable Cas12b from *Brevibacillus* sp. SYP-B805 (BrCas12b) that outperformed previous platforms in a one-pot detection setting. Nevertheless, the thermostable nature of BrCas12b only allowed this system to work robustly up to 63.4°C¹⁰.

Previous studies have shown that engineering the crRNA for Cas12a enhances its trans-cleavage activity^{30,36}. However, the thermostability of Cas enzymes is mainly linked to their secondary and tertiary structures^{37,38}. Therefore, rather than focusing on modifying sgRNA for BrCas12b, we aimed to engineer the enzyme itself not only to boost its activity but also its thermostability for better synergy with the RT-LAMP reaction. We employed structure-guided rational design to identify amino acid positions where mutations would likely be beneficial. To accomplish this, we predicted the structure of BrCas12b utilizing both AlphaFold and SWISS-MODEL followed by sequence alignment of these models with the most homologous solved Cas12b ortholog, BthCas12b (PDBID: 5WTI)^{12-15,17,39}, to identify functional domains. Overall, the AlphaFold and SWISS-MODEL predictions were congruent with one another with the exception of two minor regions close to the RuvC domains (Figure 1B). We next processed these predicted models via DeepDDG, a neural network-based algorithm to generate a fitness landscape of all amino acid positions¹⁹. We observed that the majority of the mutations were destabilizing except for hydrophobic substitutions in the REC1, RuvC, and UK-I regions (Figure 1C). Based on Gibbs free energy changes from the fitness landscape, we analyzed these mutations individually to determine predictors of thermostability in terms of hydrophobicity, compactness, hydrogen

bonding, and salt bridges. In addition to these thermostability factors, we also applied the semi-rational protein design tool HotSpot Wizard 3.0 to select the best candidates for further validation¹⁸. We pooled a few single-point mutations that were predicted to be destabilizing according to their $\Delta\Delta G$ values as controls. We identified the three most promising candidates (F208, L795, and T874) from consensus of both algorithms and their computed mutational landscape, which inferred the probability of preservation of function (Figure 1D).

Engineered BrCas12b showed robust activity at high temperature

We expressed and purified 35 single-point mutated BrCas12b variants and characterized their thermostability and catalytic activity at different temperatures. Using differential scanning fluorimetry, we observed that 16 variants increased the melting temperatures (T_m) relative to the wild-type BrCas12b, whose apo form had a T_m of 61.4°C. Five variants (F208W, D567W, D868I, D868V, and D951F) displayed an increase of more than 2°C in their T_m compared to the wild-type (Figure 2A and Figure S1). To investigate whether a combination of these stabilizing mutations would display an additive effect on the overall stability of the protein, we stacked beneficial mutations on top of each other to create several multi-mutated variants. We observed that the majority of stacked mutations such as F208W/D868V (FD), F208W/N524V/D868V (FND), F208W/N524V/T874H (FNT(H)), and F208W/N524V/L795I/D868V (FNLD) exhibited an overall additive increase of T_m ; however, there were a few exceptions—for instance, F208W/N524V/T874S (FNT(S)) and F208W/N524V/L795I/D868V/T874S/A1015E (FNLDTA) decreased thermostability upon stacking (Figure 2A-C).

We performed an *in vitro* trans-cleavage assay on all variants to check for functional preservation at elevated temperatures. While the wild-type BrCas12b variants ceased to work above 65°C (possibly due to denaturation at high temperature), the engineered BrCas12b variants FN, FND, FNT(S), FNLD, RFND, and FNLDTA showed robust activity up to 68°C (Figure 2D and Figure S2). We also observed that some stabilizing mutants like D567W, T874H, and D951F were no longer active; by examining the predicted structure, we learned that these mutations were in the RuvC and UK-I regions and potentially effected Cas12b-mediated cleavage activity. We next sought out to characterize the accuracy of both the AlphaFold and SWISS-MODEL predictions by comparing the computationally predicted single-point mutants with the experimental observations. For the SWISS-MODEL, only 13 out of 25 mutants were experimentally consistent with the software calculations, yielding a prediction accuracy of 52%. On the other hand, the AlphaFold model resulted in 15 out of 25 correct mutants, yielding a higher prediction accuracy of 60% (Figure 2E-F).

Engineered BrCas12b exhibited improved thermostability while maintaining specificity compared to its wild type

We next carried out time-dependent trans-cleavage assays to investigate the stability of BrCas12b variants compared to its wild type. Ribonucleoprotein complexes (RNP) were incubated between 10 and 60 minutes at different temperatures ranging from 60°C to 75°C. The dsDNA target and fluorescence-based reporter were then added to the RNP complex to initiate non-specific ssDNA cleavage. Based on kinetic measurements, we observed that the FND and RFND (R160E/F208W/N524V/D868V) variants showed robust trans-cleavage activity at 68°C when the RNP complex was incubated for up to 20 minutes and 50 minutes, respectively. On the other hand, the

wild-type BrCas12b failed to have detectable trans-cleavage activity under the same conditions (Figure 3A-C). To investigate the specificity of these BrCas12b variants, we designed the dsDNA target with single-point or double-point mutations across its first 10 bases proximal to the PAM site. While the FND variants showed comparable specificity to the wild-type BrCas12b, the RFND displayed a much lower tolerance to double-point mutations near the seed region than that observed in wild-type BrCas12b (Figure 3D-F). Overall, the RFND variant exhibited the highest thermostability and specificity among all the variants tested.

We hypothesized that the mutations F208W, N524V, and D868V contributed to the increase in melting temperature while the R160E mutation enhanced the enzyme activity. By looking at the BrCas12b predicted structure closely, we observed that the tryptophan at position 208 further stabilized the interaction with His394 likely by hydrophobic π - π stacking and the formation of an extra hydrogen bond with Glu422⁴⁰. Through biochemical assays, this mutation was observed to be the most contributing factor to the overall thermostability of the enzyme. Val868 allowed for improved compactness in the hydrophobic core of the RuvC region through more interactions with nearby hydrophobic residues (Figure 3G). For the mutation R160E, we did not observe an increase in the melting temperature via differential scanning fluorimetry; however, its trans-cleavage activity was higher than the wild-type BrCas12b. We hypothesized that the conversion of R160E to a negatively charged residue may have subsequently led to the enhancement in dsDNA cleavage.

Engineered BrCas12b variants showed robust activity up to 67°C in a RT-LAMP-mediated one-pot reaction

We aimed to investigate the thermostability of several engineered BrCas12b effectors in a one-pot setting. To accomplish this, we employed a LAMP primer set described in Broughton et al.² that was used to detect SARS-CoV-2 N-gene and tested them at high temperatures ranging from 62°C to 70°C with an increment of 1°C. Interestingly, these proof-of-principle primers worked robustly up to 68°C. We next coupled some of the most promising BrCas12b variants with the RT-LAMP reaction in a single pot at different temperatures ranging from 64°C to 68°C. Notably, FND, FNLD, RFND, FNPD, and FNLDTA variants showed high detection signal at 64°C with FND, FNLD, and RFND exhibiting approximately 7-fold increase in activity compared to the wild-type BrCas12b (Figure 4A). At 65°C, the wild-type BrCas12b completely ceased activity due to denaturation at high temperatures (Figure 4B). The engineered BrCas12b variants worked robustly up to 66°C but performed poorly at 67°C, possibly due to reaching their thermostability limit (Figure 4C, D).

Recent studies have shown that additives can boost the activity of CRISPR reactions in a one-pot setting^{6,41-44}. For instance, Joung et al. used taurine in their STOPCovid reaction and observed enhanced detectable signals⁶. Proline was also added to boost Cas12a activity in a two-pot setting⁴². Therefore, we sought to leverage the one-pot reaction using BrCas12b variants by exploring several additives such as taurine, mannitol, sucrose, trehalose, and betaine (Figure S3 A-C). We selected the FNLDTA variant for testing as it showed the highest fluorescence signal at 67°C (Figure 4D). We discovered that adding sucrose to the one-pot reaction at a final concentration of 200 mM greatly enhanced eBrCas12b enzymatic activity up to approximately 2.5-fold (Figure 4E). We then applied 200 mM sucrose to the remaining variants and found that sucrose was able to restore their activity at 67°C (Figure 4F and Figure S3 A-C). Interestingly, we also observed that the activity of RFND was not

enhanced at 64°C and 65°C but rather slightly reduced when 200 mM of sucrose was incorporated into the one-pot reaction. We hypothesized that sucrose helps restore the function of RFND at the upper temperature limit and does not act as an enhancer but rather as a stabilizer against chemical denaturants and temperature by altering the protein solvation state and its interaction with the surroundings⁴⁵⁻⁴⁷ (Figure S3 D-F). We coined the one-pot assay utilizing the RFND variant and optimized sucrose condition as SPLENDID (Single-pot LAMP-mediated engineered BrCas12b for nucleic acid detection of infectious diseases).

CRISPR-Cas12b-mediated cleavage and detection of dsDNA are dependent on the presence of a short protospacer adjacent motif (PAM) upstream of the target sequence. It was empirically determined that the canonical PAM for BrCas12b was TTN^{26-28,48}. However, we speculated that when targeting ssDNA, a PAM sequence may not be required as it shares similar enzymatic activity with Cas12a²³. Since the RT-LAMP reaction can result in ssDNA byproducts due to its loop-forming nature at elevated temperatures⁷, we hypothesized that PAMless or near-PAMless detection could be achieved by our RT-LAMP-coupled one-pot assay. This could potentially alleviate some challenges in primer and guide RNA designs. To investigate the PAM-dependency of eBrCas12b, we designed a PAM library of dsDNA activators that were comprised of all possible 3-nucleotide PAM sequences (NNN). We first sought to test the trans-cleavage of the RFND variant against these PAM combinations without the RT-LAMP step. We observed that the TTN-PAM containing activators displayed the highest activity with the engineered Cas12b, consistent with previous studies. We also noticed significant trans-cleavage activity with activators containing the ATA, ATT, and ATC PAM but not with ATG. Similarly, TAA-, TAT-, and TAC-containing activators had low levels of detection, but not with TAG. Our results indicate that the presence of a

single T at either the first or the second position is sufficient to initiate the trans-cleavage of eBrCas12b provided that the third position contains A,T, or C. We next tested the detection of all the PAM-library activators in a one-pot setting (with RT-LAMP amplification). We observed that while the TTH PAM containing activators had the most robust detection, a majority of non-canonical PAM containing sequences also showed detection, albeit at lower levels—the only exceptions being CTC, CGC, and CCC PAMs, which showed no detection (Figure 4G, H). Our results demonstrate that it is possible to target a variety of non-canonical PAM sequences if amplified by RT-LAMP in a one-pot assay.

Validation of SPLENDID in Hepatitis C and SARS-CoV-2 infected samples

Screening for Hepatitis C (HCV) is of high importance for early treatment since there are no vaccines available⁴⁹⁻⁵¹. Individuals infected with HCV can be cured within 8 to 12 weeks when the virus is detected early; otherwise, cirrhosis, hepatocellular carcinoma, and potential death can occur if left unnoticed^{51,52}. Traditional antibody assays offer up to 98% sensitivity and 99% specificity; however, these assays cannot distinguish between past and active infection. On the other hand, quantitative HCV RNA tests also exhibit similar sensitivity, specificity, and low limit of detection (10 - 15 IU/mL)⁵³⁻⁵⁵, but these detection platforms are laborious, time-consuming, and uneconomical. Therefore, as a proof of concept, we sought to develop a simple, rapid test for HCV using SPLENDID.

Prior to testing, a single-guide RNA was designed to target the 5' untranslated region (5' UTR) of the HCV RNA (+) genome (Figure 5A and Table S1). We then proceeded to clinically validate SPLENDID in 80 human serum samples (40 HCV-infected samples and 40 negative samples). Within the 40 HCV-infected samples, we

had a genotypic distribution as follows: 34 samples of HCV genotype 1 (GT1), 4 samples of HCV genotype 2 (GT2), and 2 samples of HCV genotype 3 (GT3). We used LAMP primers as described in the study by Hongjaisree et al.⁵⁶ but modified the FIP primer to make space for the guide-RNA binding. Crude samples were processed via a magnetic-based extraction to isolate viral RNA. These samples were randomized and blinded before undergoing SPLENDID testing (Figure 5B). Additionally, we performed an in-house RT-qPCR assay to determine the Ct value of each sample and compare the results with the clinically validated viral loads provided by HCV Target and Boca Biologic (Figure S4). All fluorescence-based measurements were compared to the RT-qPCR results to determine the sensitivity, specificity, and accuracy. Overall, we observed 7 false negatives and 1 false positive, achieving a specificity of 97.5%, an accuracy of 90.0%, and sensitivity of 82.5% (Figure 5C, D). However, genotype-specific measurements indicated that we had a sensitivity of 91% (GT1), 50% (GT2), and 0% (GT3), respectively (Table S2). Our results show that while the LAMP primers and guide RNA used in this study work robustly for HCV GT1, they perform poorly with other HCV-genotypes. HCV-GT2 contains multiple mutations within the LAMP primer binding region as well as the guide RNA binding region, which might explain the poor performance of our test with that genotype. The performance of SPLENDID for the detection of diverse HCV-genotypes can be improved simply by designing LAMP primers and guide RNA to be more specific to the target genotype. When analyzing the patient sample fluorescence results via a receiver operating characteristic curve (ROC) for the SPLENDID assay at $t = 25$ minutes, we observed that the area under the curve (AUC) was 92.3%, indicating a high threshold for differentiation between positive and negative samples (Figure 5E).

Another clinically relevant disease that requires surveillance testing is COVID-19. SARS-CoV-2 quickly sparked a global pandemic and has become increasingly contagious. We therefore tailored the SPLENDID assay to detect SARS-CoV-2 in patient samples. Specifically, we targeted the N gene, which is less likely to mutate. We performed the one-pot assay on 66 SARS-CoV-2 saliva samples (29 positive and 37 negative) using SYTO™ 9 to track the RT-LAMP amplification and a FRET-based HEX reporter to monitor the trans-cleavage activity of the eBrCas12b RFND. We observed that the RT-LAMP reaction resulted in a high false positive rate (8 out of 37 negative samples were false positives). On the other hand, the SPLENDID assay produced no false positives (Figure S5A, B). Overall, the RT-LAMP reaction alone achieved 78.4% specificity, 86.4% accuracy, and 96.6% sensitivity; the SPLENDID assay attained 100% specificity, 97.0% accuracy, and 93.1% sensitivity (Figure S5). These results further solidified the importance of having the CRISPR-eBrCas12b in the rapid one-pot reaction to increase the specificity and accuracy of nucleic acid detection.

DISCUSSION

CRISPR-based diagnostics offer many advantages over traditional testing methods for nucleic acid detection due to their high specificity, flexible programmability, and quick turnaround time. To increase sensitivity, the CRISPR reaction is often paired with a pre-amplification step such as RT-RPA (reverse transcription recombinase polymerase amplification) or RT-LAMP. Here we report an engineered CRISPR-Cas12b system (eBrCas12b) with substantial improvements in terms of thermostability compared to other CRISPR-based one-pot assays.

Out of several mutations introduced to the wild-type BrCas12b to create engineered variants, we observed a substantial improvement in thermostability of the proteins at two residues, F208W and D868V, each with around 2°C increase in melting temperature compared to the wild type. Structurally, these two residues are located at two distinct regions of the protein, with F208 at the intersection of the PAM-interacting domain and REC1 and with D868 being proximal to the catalytic pocket RuvCII domain. We hypothesized that F208W enabled enhanced π - π stacking with its neighbor H394 while D868V increased the compactness of its local region by increasing the hydrophobic surface interactions with its surrounding.

Our engineered detection assay using eBrCas12b, which we coined SPLENDID, works robustly up to 67°C in a one-pot setting, encompassing the optimal temperature range of the RT-LAMP reaction. SPLENDID combines two promising rapid detection platforms, amplification-based RT-LAMP and CRISPR assays, into a single pot reaction with improved synergy for a robust two-step verification for the presence of target nucleic acids: 1) amplification of target and 2) collateral cleavage of BrCas12b. We applied SPLENDID to clinically validate 80 HCV and 66 SARS-CoV-2 patient samples. Early detection of HCV and SARS-CoV-2 is important for preventing acute complications and contagion. Current testing methods are costly, require specialized personnel and equipment, and may not distinguish between active and past infections. Our SPLENDID system utilizing the engineered thermostable BrCas12b (eBrCas12b) was able to successfully detect the presence of HCV in human serum samples with a specificity of 97.5%, an accuracy of 90.0% (overall) to 94.6% (GT1), and sensitivity of 82.5% (overall) to 91.1% (GT1). For SARS-CoV-2 testing, the assay achieved 97.0% accuracy, 100% specificity, and 93.1% sensitivity (Figure S5).

Compared to other CRISPR-based and non-CRISPR-based detection platforms, the SPLENDID assay demonstrated similar accuracy, specificity, and sensitivity while being a more rapid and convenient one-pot reaction with the potential to be deployed outside the standard lab setting (Table S3). This detection platform can be applied towards many other pathogens due to the flexible programmability of the guide RNA design. We speculate that the sensitivity of our clinical validation testing heavily relied on quality of LAMP primer design. As a result, one way to improve the assay is to test many more LAMP primers to obtain the most optimal set.

Additionally, the SPLENDID assay can be performed in as little as 20 minutes, and the whole process including sample extraction takes up to an hour. If paired with a more rapid extraction method, the overall assay duration can be reduced. Additionally, one-pot reagents can potentially be lyophilized as we discussed in our previous study, thus allowing for administration in low-resource areas¹⁰. We believe that the SPLENDID system has wide applications for detection of emerging infectious diseases and can be quickly deployed to regions of interest at low cost.

Cas12b has been successfully repurposed for gene editing through protein engineering²⁶. We observed that several point mutations to the wild-type BrCas12b decreased its melting temperature while maintaining the dsDNA cleavage capability. Therefore, we believe that these mutations can be stacked to create lower melting point Cas12b variants capable of dsDNA cleavage at 37°C to be used for gene editing. Additionally, due to the similarity in structure and cleavage patterns between Cas12a and Cas12b, we imagine that the Cas12b can further be engineered to carry out precision base editing without dsDNA breaks^{57,58}. The design approaches of BrCas12b

presented here demonstrate new engineering strategies for the use of CRISPR-Cas systems in diagnostics and potentially therapeutic applications.

Limitations of the Study

While SPLENDID offers many advantages as a rapid point-of-care diagnostic tool, we acknowledge that it has some limitations. SPLENDID still heavily relies on the robustness of the RT-LAMP reaction due to the low sensitivity of the trans-cleavage activity of CRISPR-Cas systems. Therefore, careful design of LAMP primers is crucial for the success of the assay. Additionally, although SPLENDID exhibited high sensitivity when validated in SARS-CoV-2 patient samples (93.1%), its sensitivity towards HCV patient samples was significantly lower (82.5%). For this reason, the assay needs further optimization to become practical for HCV on-field testing.

STAR★Methods

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Patient details
 - Cell lines
- METHOD DETAILS
 - Computational Analyses
 - Nucleic Acid Preparation
 - Site-directed Mutagenesis
 - Protein Expression and Purification
 - Differential Scanning Fluorimetry
 - Temperature- and time-dependent trans-cleavage assay
 - One-pot RT-LAMP-coupled BrCas12b detection assay
 - PAM library

- Patient samples extraction and processing
- RT-qPCR of HCV and SARS-CoV-2 clinical samples
- QUANTIFICATION AND STATISTICAL ANALYSIS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and virus strains		
Rosetta™ 2(DE3)pLysS Singles Competent Cells	Millipore Sigma	Cat# 71401
NEB® 5-alpha Competent <i>E. coli</i> (High Efficiency)	New England Biolabs	Cat# C2987H
Biological samples		
HCV infected Patient Serum Samples	HCV- TARGET	N/A
Healthy Patient Serum Samples	Boca Biologics	N/A
SARS-CoV-2 Infected Patient Saliva Samples	Clinical and Translational Biorepository; University of Florida	N/A
Chemicals, peptides, and recombinant proteins		
SYTO™ 9 Green Fluorescent Nucleic Acid Stain	Thermo Fisher Scientific	Cat# S34854
IPTG	Gold Biotechnology	Cat# I2481C
NaCl	Fisher Scientific	Cat# BP358-212
Tris-HCl	Gold Biotechnology	Cat# T-095-100
Thermo Scientific™ PMSF Protease Inhibitor	Fisher Scientific	Cat# 36978

TCEP-HCl	Gold Biotechnology	Cat# TCEP1
Lysozyme	MP Biomedicals, LLC	Cat# 02100831-CF
Imidazole	AmBeed	Cat# A277098
Deoxyribose Nuclease I (Bovine Pancreas)	Worthington Biochemical Corporation	Cat# LS002145
Q5® polymerase	New England BioLabs	Cat# M0491S
TEV protease	Kapust et al.	Addgene #8827
HEPES	Sigma Aldrich	Cat# H3375-500G
Critical commercial assays		
Q5® Site-Directed Mutagenesis Kit	New England BioLabs	Cat# E0554S
WarmStart® Multi-Purpose LAMP/RT-LAMP 2X Master Mix (with UDG)	New England BioLabs	Cat# M1708S
Luna® Probe One-Step RT-qPCR 4X Mix with UDG	New England BioLabs	Cat# M3019S
NEBuilder® HiFi DNA Assembly Cloning Kit	New England BioLabs	Cat# E5520S
Protein Thermal Shift™ Dye Kit	Thermo Fisher Scientific	Cat# 4461146
Quick-DNA/RNA Viral MagBead Kit	Zymo Research	Cat# R2140
Deposited data		
6xHis-MBP-BrCas12b-RFND	This Paper	Addgene# 195339
6xHis-MBP-BrCas12b-FNLDTA	This Paper	Addgene# 195340
Oligonucleotides		

RT-LAMP Primers SARS-CoV-2, see Table S1	Broughton et al	N/A
RT-LAMP Primers 5' UTR of Hepatitis C, see Table S1	Hongjaisee et al	N/A
RT-qPCR HCV Primers and Probes, see Table S1	Zauli et al	N/A
RT-qPCR HCV Modified ZEN Probe, see Table S1	Integrated DNA Technologies	N/A
Single-guide RNA Br_sgN_CoV2, see Table S1	This Paper; Synthesized by Integrated DNA Technologies	N/A
Single-guide RNA Br_sgUTR_HCV, see Table S1	This Paper; Synthesized by Integrated DNA Technologies	N/A
Reporter 1: /5HEX/TTTTTTTT/3IABkFQ/	This Paper; Synthesized by Integrated DNA Technologies	N/A
Reporter 2: /5FAM/TTTTTTTTTT/3IABkFQ/	This Paper; Synthesized by Integrated DNA Technologies	N/A
SARS-CoV-2 Activator PAM Library	Twist Biosciences	N/A
Recombinant DNA		
6xHis-MBP Destination Vector	Gift from Scott Gardia	Addgene# 29656
pET28a+ Vector	Shilling et al.	Addgene# 154464
Software and algorithms		
ColabFold	Mirdita et al.	https://github.com/sokrypton/ColabFold
SWISS-MODEL	Waterhouse et al.	https://swissmodel.expasy.org/

HotSpot Wizard 3.0	Sumbalova et al.	https://loschmidt.chemi.muni.cz/hotspotwizard/
DeepDDG	Cao et al.	http://protein.org.cn/ddg.html
NEB LAMP Primer Design Tool	New England Biolabs	https://lamp.neb.com/#/
PrimerExplorer v5	Eiken Chemical Co.	https://primerexplorer.jp/e/
GraphPad Prism 8	GraphPad Software	https://www.graphpad.com/scientificsoftware/prism/
Other		
Luria Broth	Fisher Scientific	Cat# BP9723-500
Terrific Broth	Cold Spring Harbor Protocols	http://cshprotocols.cshlp.org/content/2015/9/pdb.rec085894.full?rss=1
SOC Medium	New England Biolabs	B9020S
Antifoam 204	Millipore Sigma	Cat# A8311-50ML
NEBuffer 2.1	New England Biolabs	Cat# B9200S
10X Nuclease-Free Duplex Buffer	Integrated DNA Technologies	Cat# 11-05-01-12
Histrap 5 mL FF Column	Cytiva Life Sciences	Cat# 17524802
HiTrap 1 mL SP HP Column	Cytiva Life Sciences	Cat# 29051324
0.22-Micron Filter	Millipore Sigma	Cat# GSWP14250
SDS-PAGE 4-12% Gels	Genscript	Cat# M00653
50 kDa MWCO Amicon Ultra-15 Filter	Millipore Sigma	Cat# UFC9050

RESOURCE AVAILABILITY

Lead Contact

Further inquiries and information regarding resources and reagents should be directed to and will be fulfilled by the Lead Contact, Piyush Jain (jainp@ufl.edu).

Materials Availability

Distribution of engineered BrCas12b mutant plasmids can be found on Addgene (plasmid # 195339 for 6xHis-MBP-BrCas12b-RFND and plasmid # 195340 for 6xHis-MBP-BrCas12b-FNLDTA).

Data and Code Availability

- All data are presented in the main text as well as in the supplementary information. Predicted structures of all BrCas12b variants are included in the source files attached to this manuscript.
- This paper does not contain original code.
- Any additional information required to re-analyze the data reported in this work paper is available from the Lead Contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Patient Details

For this study, de-identified patient sample collection and processing were approved as a non-human study by the University of Florida Institutional Review Board (IRB202003085) and all ethical regulations were followed. For clinical validation, 80 patient samples consisting of human serum were obtained, 40 of which were HCV- positive and collected and de-identified by HCV-TARGET consortium; the other 40 derived from healthy patients were obtained from a commercial vendor, Boca Biolistics. All HCV-positive samples were collected by HCV-TARGET with obtaining a written informed consent from the patient. All healthy samples were procured by Boca Biolistics from their network of CAP/CLIA accredited partner

laboratories across the United States as remnant (leftover) samples. These samples were delinked under the IIRB delinking protocol SOP 10-00114 Rev E.

Males and females greater than or equal to age 18 years who tested positive for HCV by an RNA test were included as positive. Males and females greater than or equal to age 18 years who tested negative for HCV by an RNA test were included as negative. For positive samples, fibrosis stage and prior treatment information is included in the supplementary information. Viral RNA was extracted from serum samples using Quick-DNA/RNA Viral MagBead Kit R2140 (Zymo Research). Extracted patient samples were chosen at random and blinded for one-pot testing.

Cell Lines

All BrCas12b variants were expressed in Rosetta™ 2(DE3)pLysS Singles™ Competent Cells (purchased from Millipore Sigma). Cells were kept frozen at -80°C until use. Cells were cultured as per supplier's protocol with slight modifications. For transformation, frozen cells were thawed and then incubated with plasmids for 5 minutes on ice, heat-shocked for 30 seconds at 42°C in a water bath, placed back on ice for 2 minutes, and then cultured at 37°C in SOC medium (New England Biolabs) at 250 rpm for 1 hour before spreading on antibiotic-containing agar plates. After spreading, the plates were incubated at 37°C for 12-48 hours and then the colonies were picked, expanded in 10 mL Luria Broth (Fisher Scientific) containing the appropriate antibiotics, and sequenced by Sanger sequencing. Please refer to Protein Expression and Purification section for more details.

METHOD DETAILS

Computational Analyses

Protein structure predictions were performed on a local install of ColabFold with “AlphaFold2-ptm” parameters using A100 GPUs, where MSA search was done by MMseqs2 on UniRef100 database⁵⁹. For SWISS-MODEL predictions, protein sequences were input into the web-based tool via Expasy web server^{13,15-17,60}. Protein structures in pdb files were processed via both HotSpot Wizard 3.0¹⁸ and DeepDDG¹⁹ web-based software.

Nucleic Acid Preparation

Double-stranded DNA targets, single-guide RNAs, and fluorescence-quencher reporters were synthesized by Integrated DNA Technologies (IDT). PAM Library targets for SARS-CoV-2 N gene was designed and synthesized by Twist Bioscience. For the trans-cleavage assay without RT-LAMP, the target-strand (TS) and non-target-strand (NTS) activators were ordered as 60-mer ssDNA oligos and annealed in a 5:1 (NTS:TS) ratio in 1X nuclease-free duplex buffer (IDT).

Site-directed Mutagenesis

The wild-type BrCas12b gene was codon-optimized for *E. coli* expression, synthesized by Twist Bioscience, and cloned into pET28a⁺ vector. For a mutant with single-point or double-point mutations, mutagenesis was carried out using the Q5® Site-Directed Mutagenesis Kit (New England Biolabs) following the manufacturer’s protocols. For simultaneous triple-point mutations, primers with intended mutations were designed and used to amplify each fragment of the BrCas12b using Q5® polymerase and assembled into a 6xHis-MBP destination vector (a gift from Scott Gardia, Addgene# 29656) using NEBuilder® HiFi DNA Assembly Kit (New England Biolabs).

Protein Expression and Purification

Expression and purification of BrCas12b variants were performed according to a previous study with minor modifications¹⁰. After transforming BrCas12b variants into Rosetta™ 2(DE3) pLysS Singles™ Competent Cells (Millipore Sigma), individual colonies were selected and propagated overnight (12-15 hours) in 10 mL of Luria Broth (Fisher Scientific) containing the appropriate antibiotics. The bacterial cultures were then scaled up in 2 L of Terrific Broth containing the corresponding antibiotics and 5 drops of antifoam 204 (Sigma Aldrich). Once an OD₆₀₀ of 0.5-0.8 was attained, the culture was cooled in an ice bath for 30 mins, induced with 0.2 mM IPTG (isopropyl β-D-1-thiogalactopyranoside), and shaken at 18°C overnight (14-18 hours). The bacterial cells were then pelleted (39,800 xg at 4°C), diluted in lysis buffer (0.5 M NaCl, 50 mM Tris-HCl, pH = 7.5, 1 mM PMSF, 0.5 mM TCEP, 0.25 mg/ml lysozyme, and 10 mg/mL deoxyribose nuclease I), and disrupted by sonication. The lysed cells were then spun down (39,800 xg at 4°C), and the supernatant was subjected to suction filtration through a 0.22-micron filter (Millipore Sigma). The filtered solution was purified using an FPLC Biologic Duoflow system (Bio-rad) through a Histrap 5 mL FF column (Cytiva), which was then washed (wash buffer: 0.5 M NaCl, 50 mM Tris-HCl, pH = 7.5, 20 mM Imidazole, 0.5 mM TCEP) before eluting (elution buffer: 0.5 M NaCl, 50 mM Tris-HCl pH = 7.5, 300 mM imidazole, 0.5 mM TCEP). For BrCas12b variants that were cloned into the 6xHis-MBP destination vector, an extra step of TEV site cleavage was performed to remove the MBP tag, and the protein was processed using Hitrap Heparin HP (Cytiva) purification. The elution was evaluated using SDS-PAGE; the fractions containing the protein were consolidated and concentrated (2000 xg at 4°C) in a 50 kDa MWCO Amicon Ultra-15 centrifugal filter unit (Millipore Sigma). The protein

was stored in -20°C for further use, with back-up reserves of each protein kept at -80°C after dilution (buffer C: 150 mM NaCl, 50 mM HEPES, pH = 7, 0.5 mM TCEP).

Differential Scanning Fluorimetry

The melting temperature of each protein was mainly carried out in its apo form. BrCas12b was mixed in Protein Thermal Shift™ buffer (Thermofisher) in combination with 1x reaction buffer (100 nM NaCl, 50 nM Tris-HCl, pH=7.5, 1mM DTT, and 10 mM MgCl₂) to a final concentration of 500 nM. Protein Thermal Shift dye™ (Thermofisher) was then added to each mixture before being transferred to the qPCR StepOne Plus system (Thermofisher). The temperature profile was observed over a temperature range of 25°C-80°C at a ramp rate of 1%/s. Experiments were performed in duplicates and repeated twice.

Temperature- and time-dependent trans-cleavage assay

The thermostable BrCas12b variants and sgRNA were combined in 1x NEBuffer 2.1 (New England Biolabs) to a final concentration of 50 nM : 100 nM (sgRNA : BrCas12b) and then transferred to a pre-heated CFX96 Real-Time PCR system with C1000 Thermal Cycler module (Bio-rad) using a temperature gradient setting across each row, ranging from 60°C to 75°C (60°C, 61°C, 63°C, 65.9°C, 69.5°C, 72.5°C, 74.2°C, and 75°C). The ribonucleoprotein complexes were incubated for 10 - 60 minutes with an increment of 10 minutes. A fluorescence-based reporter (FQ) and dsDNA activator were then added to each mixture to a final concentration of 250 nM and 1 nM, respectively. The reactions were isothermally incubated at their corresponding complexation temperature for consistency. Fluorescent measurements were taken every 30 seconds for 120 cycles on the HEX channel (λ_{ex} : 525/10 nm, λ_{em} : 570/10 nm). This experiment was repeated at incubation temperatures of 67°C and

68°C without the gradient setting to cover a better temperature distribution. All experiments were repeated twice.

One-pot RT-LAMP-coupled BrCas12b detection assay

LAMP primers were designed using NEB® LAMP Primer Design Tool from New England Biolabs (<https://lamp.neb.com/#!/>) and PrimerExplorer v5 from Eiken Chemical Co. (<https://primerexplorer.jp/e/>).

BrCas12b variants, single-guide RNA, fluorescence-quencher reporter, and 10x LAMP primers were combined in 1x Warmstart® Multi-Purpose/RT-LAMP Master Mix with UDG (New England Biolabs) to a final concentration of 200 nM, 400 nM, 2000 nM, and 1x LAMP primers (200 nM F3/B3, 1600 nM FIP/BIP, and 800 nM LF/LB), respectively, yielding a volume of 22 mL. The activator (dsDNA/RNA) was added to the mixture (25 mL final volume), and the reaction was then transferred to a CFX96 Real-Time PCR system with a C1000 Thermal Cycler module (Bio-rad). Fluorescence measurements were taken every 30 seconds per cycle for 120 cycles.

PAM library

For trans-cleavage assays without the RT-LAMP step, BrCas12b and sgRNA activators were combined to a final concentration of 100 nM: 50 nM respectively in 1x NEBuffer 2.1 (New England Biolabs) and incubated at 65°C for 15 min. Fluorescence-based reporter (FQ) and 25 nM activators containing various PAM sequences were added to the reaction mixture containing the Cas12b: sgRNA complex to a final concentration of 250 nM and 1 nM, respectively. The entire reaction was then immediately transferred to a Bio-rad CFX96 Real-Time system with C1000 Thermal

Cycler module. The reaction was isothermally incubated at 65 °C, and fluorescence measurements were read every 30 seconds per cycle over 120 cycles.

In the experiment with RT-LAMP, the one-pot BrCas12b detection assay method was utilized. 3 µL of 10 pM activators containing various PAM sequences were added to the reaction. Both experiments were carried out in duplicates and repeated twice.

Patient samples extraction and processing

The Quick-DNA/RNA™ Viral MagBead extraction was conducted according to manufacturer protocol. 10 µL of Proteinase K (20mg/mL) was combined with 200 µL of serum samples in 1.5 mL centrifuge tubes and incubated at room temperature (RT) for 15 minutes. DNA/RNA Shield™ (2x concentrate) was added to the serum sample containing Protease K in a 1:1 ratio. 800 µL Viral DNA/RNA Buffer was then incorporated into the combined mixture followed by the addition of 20 µL MagBinding Beads™ and vortexed for 10 minutes. The centrifuge tubes were placed in a magnetic stand until the beads were pelleted. The supernatant was aspirated and discarded. The beads were washed with 250 µL of MagBead DNA/RNA Wash 1, 250 µL MagBead DNA/RNA Wash 2, and two rounds of 250 µL of 100% ethanol. The tubes containing beads were air-dried for 10 minutes. DNA/RNA was eluted using 30 µL DNase/RNase-Free water and was subjected to a BrCas12b detection reaction.

RT-qPCR of HCV and SARS-CoV-2 clinical samples

HCV-specific primers and probe sequences were designed as described in Zauli et. al⁶¹. The probe was modified by adding an internal ZEN™ quencher from IDT to reduce the background signal. C_t values for 80 HCV serum and 66 SARS-CoV-2

saliva samples were obtained by using Luna® Probe One-Step RT-qPCR 4X Mix with UDG (NEB# M3019S) and following manufacturer's protocol. Briefly, Luna® Probe One-Step RT-qPCR 4X Mix with UDG, forward and reverse primers, and probe were combined to a final concentration of 1x, 0.4 μ M (each), and 0.2 μ M, respectively. Once assembled, the master mix was added to a 96-well plate (Applied Biosystems). 3 μ L of extracted patient sample were deposited in each well, to a total volume of 20 μ L, to initiate the reaction. The 96-well plate was then inserted into the StepOnePlus Real-Time PCR system (Applied Biosystems), which set auto threshold to calculate the Ct values.

QUANTIFICATION AND STATISTICAL ANALYSIS

Patient samples containing positive HCV and SARS-CoV-2 pathogens were randomized and blinded. Data were analyzed and visualized using GraphPad Prism 8 (GraphPad Software, San Diego, CA) and results were expressed as means \pm SD.

ACKNOWLEDGEMENT

We are grateful to the entire HCV-TARGET consortium, particularly the principal investigator, Dr. David Nelson, and the staff member, Lauren Morelli, at the University of Florida for providing us with their expert guidance and clinical samples for this study. We are thankful to the past and current members of Jain Lab and Dr. Gary Wang's Lab at the University of Florida for their insightful feedback.

AUTHOR CONTRIBUTIONS

P.K.J., L.T.N., S.R.R., L.G.Y., and N.C.M. designed the experiments. L.T.N., S.R.R., L.G.Y., and N.C.M. mainly performed experiments with support from other co-authors. L.C. and A.P. performed AlphaFold predictions of all BrCas12b variants.

L.T.N., S.R.R., and L.G.Y. wrote the initial manuscript with support from the rest of the co-authors. The manuscript was proofread, edited, and approved by all authors.

DECLARATION OF INTERESTS

L.T.N., S.R.R., and P.K.J. are listed as inventors on the patent applications related to the content of this work. P.K.J. is a co-founder of Genable Biosciences, LLC, Par Biosciences, LLC, and CRISPR, LLC. The remaining authors declare no competing interests.

INCLUSION AND DIVERSITY

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community.

FUNDING

This work was financially supported by funds from the University of Florida (UF) and the UF Herbert Wertheim College of Engineering, Dinesh O. Shah endowed professorship, NIH-NIAID R21AI156321, NIH-NIAID R21AI168795, and NIH-NIGMS R35GM147788. The funding sources did not have a role in the design of the study, the collection, analysis, or interpretation of data, nor in the writing of the manuscript.

REFERENCES

1. Gootenberg, J.S., Abudayyeh, O.O., Lee, J.W., Essletzbichler, P., Dy, A.J., Joung, J., Verdine, V., Donghia, N., Daringer, N.M., Freije, C.A., et al. (2017). Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* 356, 438-+. 10.1126/science.aam9321.
2. Broughton, J.P., Deng, X., Yu, G., Fasching, C.L., Servellita, V., Singh, J., Miao, X., Streithorst, J.A., Granados, A., Sotomayor-Gonzalez, A., et al. (2020). CRISPR-Cas12-based detection of SARS-CoV-2. *Nat Biotechnol* 38, 870-874. 10.1038/s41587-020-0513-4.
3. Patchsung, M., Jantarug, K., Pattama, A., Aphicho, K., Suraritdechachai, S., Meesawat, P., Sappakhaw, K., Leelahakorn, N., Ruenkam, T., Wongsatit, T., et al. (2020). Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. *Nat Biomed Eng* 4, 1140-1149. 10.1038/s41551-020-00603-x.
4. Hampton, T. (2020). Virus Surveillance and Diagnosis With a CRISPR-Based Platform. *Jama-J Am Med Assoc* 324, 430-430. 10.1001/jama.2020.12669.
5. Welch, N.L., Zhu, M.L., Hua, C., Weller, J., Mirhashemi, M.E., Nguyen, T.G., Mantena, S., Bauer, M.R., Shaw, B.M., Ackerman, C.M., et al. (2022). Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants. *Nat Med* 28, 1083-+. 10.1038/s41591-022-01734-1.
6. Joung, J., Ladha, A., Saito, M., Kim, N.G., Woolley, A.E., Segel, M., Barretto, R.P.J., Ranu, A., Macrae, R.K., Faure, G., et al. (2020). Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. *N Engl J Med* 383, 1492-1494. 10.1056/NEJMc2026172.
7. Notomi, T., Okayama, H., Masubuchi, H., Yonekawa, T., Watanabe, K., Amino, N., and Hase, T. (2000). Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* 28, E63. 10.1093/nar/28.12.e63.
8. Amaral, C., Antunes, W., Moe, E., Duarte, A.G., Lima, L.M.P., Santos, C., Gomes, I.L., Afonso, G.S., Vieira, R., Teles, H.S.S., et al. (2021). A molecular test based on RT-LAMP for rapid, sensitive and inexpensive colorimetric detection of SARS-CoV-2 in clinical samples. *Sci Rep-Uk* 11. ARTN 16430 10.1038/s41598-021-95799-6.
9. Huang, X., Tang, G.Y., Ismail, N., and Wang, X.W. (2022). Developing RT-LAMP assays for rapid diagnosis of SARS-CoV-2 in saliva. *Ebiomedicine* 75. ARTN 103736 10.1016/j.ebiom.2021.103736.
10. Nguyen, L.T., Macaluso, N.C., Pizzano, B.L.M., Cash, M.N., Spacek, J., Karasek, J., Miller, M.R., Lednický, J.A., Dinglasan, R.R., Salemi, M., and Jain, P.K. (2022). A thermostable Cas12b from *Brevibacillus* leverages one-pot discrimination of SARS-CoV-2 variants of concern. *Ebiomedicine* 77. ARTN 103926 10.1016/j.ebiom.2022.103926.
11. Wong, Y.P., Othman, S., Lau, Y.L., Radu, S., and Chee, H.Y. (2018). Loop-mediated isothermal amplification (LAMP): a versatile technique for detection of micro-organisms. *J Appl Microbiol* 124, 626-643. 10.1111/jam.13647.
12. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Zidek, A., Potapenko, A., et al. (2021). Highly

- accurate protein structure prediction with AlphaFold. *Nature* 596, 583-+. 10.1038/s41586-021-03819-2.
13. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bordoli, L., et al. (2018). SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Research* 46, W296-W303. 10.1093/nar/gky427.
 14. Kopp, J., and Schwede, T. (2006). The SWISS-MODEL repository: new features and functionalities. *Nucleic Acids Research* 34, D315-D318. 10.1093/nar/gkj056.
 15. Guex, N., Peitsch, M.C., and Schwede, T. (2009). Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. *Electrophoresis* 30, S162-S173. 10.1002/elps.200900140.
 16. Studer, G., Rempfer, C., Waterhouse, A.M., Gumienny, R., Haas, J., and Schwede, T. (2020). QMEANDisCo-distance constraints applied on model quality estimation (vol 36, pg 1765, 2020). *Bioinformatics* 36, 2647-2647. 10.1093/bioinformatics/btaa058.
 17. Bertoni, M., Kiefer, F., Biasini, M., Bordoli, L., and Schwede, T. (2017). Modeling protein quaternary structure of homo- and hetero-oligomers beyond binary interactions by homology. *Sci Rep-Uk* 7. ARTN 10480 10.1038/s41598-017-09654-8.
 18. Sumbalova, L., Stourac, J., Martinek, T., Bednar, D., and Damborsky, J. (2018). HotSpot Wizard 3.0: web server for automated design of mutations and smart libraries based on sequence input information. *Nucleic Acids Research* 46, W356-W362. 10.1093/nar/gky417.
 19. Cao, H.L., Wang, J.X., He, L.P., Qi, Y.F., and Zhang, J.Z. (2019). DeepDDG: Predicting the Stability Change of Protein Point Mutations Using Neural Networks. *J Chem Inf Model* 59, 1508-1514. 10.1021/acs.jcim.8b00697.
 20. Wang, X.Y., Luo, H.Y., Yu, W.N., Ma, R., You, S., Liu, W.N., Hou, L.Y., Zheng, F., Xie, X.M., and Yao, B. (2016). A thermostable *Gloeophyllum trabeum* xylanase with potential for the brewing industry. *Food Chem* 199, 516-523. 10.1016/j.foodchem.2015.12.028.
 21. Zhao, Y., Miao, Y.L., Zhi, F.D., Pan, Y., Zhang, J.G., Yang, X.P., Zhang, J.Z.H., and Zhang, L.J. (2021). Rational Design of Pepsin for Enhanced Thermostability via Exploiting the Guide of Structural Weakness on Stability. *Front Phys-Lausanne* 9. ARTN 755253 10.3389/fphy.2021.755253.
 22. Gootenberg, J.S., Abudayyeh, O.O., Kellner, M.J., Joung, J., Collins, J.J., and Zhang, F. (2018). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. *Science* 360, 439-+. 10.1126/science.aag0179.
 23. Chen, J.S., Ma, E.B., Harrington, L.B., Da Costa, M., Tian, X.R., Palefsky, J.M., and Doudna, J.A. (2018). CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science* 360, 436-+. 10.1126/science.aar6245.
 24. Li, L.X., Li, S.Y., Wu, N., Wu, J.C., Wang, G., Zhao, G.P., and Wang, J. (2019). HOLMESv2: A CRISPR-Cas12b-Assisted Platform for Nucleic Acid Detection and DNA Methylation Quantitation. *Acs Synth Biol* 8, 2228-2237. 10.1021/acssynbio.9b00209.
 25. Qiao, X., Gao, Y.M., Li, J.J., Wang, Z.G., Qiao, H.Y., and Qi, H. (2021). Sensitive analysis of single nucleotide variation by Cas13d orthologs,

- EsCas13d and RspCas13d. *Biotechnol Bioeng* 118, 3037-3045. 10.1002/bit.27813.
26. Strecker, J., Jones, S., Koopal, B., Schmid-Burgk, J., Zetsche, B., Gao, L.Y., Makarova, K.S., Koonin, E.V., and Zhang, F. (2019). Engineering of CRISPR-Cas12b for human genome editing. *Nat Commun* 10. ARTN 212 10.1038/s41467-018-08224-4.
 27. Tian, Y., Liu, R.R., Xian, W.D., Xiong, M.J., Xiao, M., and Li, W.J. (2020). A novel thermal Cas12b from a hot spring bacterium with high target mismatch tolerance and robust DNA cleavage efficiency. *Int J Biol Macromol* 147, 376-384. 10.1016/j.ijbiomac.2020.01.079.
 28. Teng, F., Cui, T., Feng, G., Guo, L., Xu, K., Gao, Q., Li, T., Li, J., Zhou, Q., and Li, W. (2018). Repurposing CRISPR-Cas12b for mammalian genome engineering. *Cell Discov* 4, 63. 10.1038/s41421-018-0069-3.
 29. Tian, Y., Liu, R.R., Xian, W.D., Xiong, M., Xiao, M., and Li, W.J. (2020). A novel thermal Cas12b from a hot spring bacterium with high target mismatch tolerance and robust DNA cleavage efficiency. *Int J Biol Macromol* 147, 376-384. 10.1016/j.ijbiomac.2020.01.079.
 30. Nguyen, L.T., Smith, B.M., and Jain, P.K. (2020). Enhancement of trans-cleavage activity of Cas12a with engineered crRNA enables amplified nucleic acid detection (vol 11, 4906, 2020). *Nat Commun* 11. ARTN 6104 10.1038/s41467-020-20117-z.
 31. Fozouni, P., Son, S.M., Derby, M.D.D., Knott, G.J., Gray, C.N., D'Ambrosio, M.V., Zhao, C.Y., Switz, N.A., Kumar, G.R., Stephens, S.I., et al. (2021). Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. *Cell* 184, 323-+. 10.1016/j.cell.2020.12.001.
 32. Liu, T.Y., Knott, G.J., Smock, D.C.J., Desmarais, J.J., Son, S., Bhuiya, A., Jakhanwal, S., Prywes, N., Agrawal, S., Derby, M.D.D., et al. (2021). Accelerated RNA detection using tandem CRISPR nucleases (vol 17, pg 982, 2021). *Nat Chem Biol* 17, 1210-1210. 10.1038/s41589-021-00882-8.
 33. Coelho, B.D., Sanchuki, H.B.S., Zanette, D.L., Nardin, J.M., Morales, H.M.P., Fornazari, B., Aoki, M.N., and Blanes, L. (2021). Essential properties and pitfalls of colorimetric Reverse Transcription Loop-mediated Isothermal Amplification as a point-of-care test for SARS-CoV-2 diagnosis. *Mol Med* 27. ARTN 30 10.1186/s10020-021-00289-0.
 34. Hardinge, P., and Murray, J.A.H. (2019). Reduced False Positives and Improved Reporting of Loop-Mediated Isothermal Amplification using Quenched Fluorescent Primers. *Sci Rep-Uk* 9. ARTN 7400 10.1038/s41598-019-43817-z.
 35. Ali, Z., Aman, R., Mahas, A., Rao, G.S., Tehseen, M., Marsic, T., Salunke, R., Subudhi, A.K., Hala, S.M., Hamdan, S.M., et al. (2020). iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. *Virus Res* 288. ARTN 198129 10.1016/j.virusres.2020.198129.
 36. Kim, H., Lee, W.J., Kim, C.H., Oh, Y., Gwon, L.W., Lee, H., Song, W., Hur, J.K., Lim, K.S., Jeong, K.J., et al. (2022). Highly specific chimeric DNA-RNA-guided genome editing with enhanced CRISPR-Cas12a system. *Mol Ther-Nucl Acids* 28, 353-362. 10.1016/j.omtn.2022.03.021.
 37. Hand, T.H., Das, A., and Li, H. (2019). Directed evolution studies of a thermophilic Type II-C Cas9. *Method Enzymol* 616, 265-288. 10.1016/bs.mie.2018.10.029.

38. Kumar, S., Tsai, C.J., and Nussinov, R. (2000). Factors enhancing protein thermostability. *Protein Eng* 13, 179-191. DOI 10.1093/protein/13.3.179.
39. Wu, D., Guan, X.Y., Zhu, Y.W., Ren, K., and Huang, Z.W. (2017). Structural basis of stringent PAM recognition by CRISPR-C2c1 in complex with sgRNA. *Cell Res* 27, 705-708. 10.1038/cr.2017.46.
40. Fernandez-Recio, J., Vazquez, A., Civera, C., Sevilla, P., and Sancho, J. (1997). The tryptophan/histidine interaction in alpha-helices. *J Mol Biol* 267, 184-197. 10.1006/jmbi.1996.0831.
41. Louwrier, A., and van der Valk, A. (2001). Can sucrose affect polymerase chain reaction product formation? *Biotechnol Lett* 23, 175-178. Doi 10.1023/A:1005656100993.
42. Li, Z.H., Zhao, W.C., Ma, S.X., Li, Z.X., Yao, Y.J., and Fei, T. (2021). A chemical-enhanced system for CRISPR-Based nucleic acid detection. *Biosens Bioelectron* 192. ARTN 113493 10.1016/j.bios.2021.113493.
43. Spiess, A.N., Mueller, N., and Ivell, R. (2004). Trehalose is a potent PCR enhancer: Lowering of DNA melting temperature and thermal stabilization of Taq polymerase by the disaccharide trehalose. *Clin Chem* 50, 1256-1259. 10.1373/clinchem.2004.031336.
44. Jensen, M.A., Fukushima, M., and Davis, R.W. (2010). DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis. *Plos One* 5. ARTN e11024 10.1371/journal.pone.0011024.
45. Lee, J.C., and Timasheff, S.N. (1981). The Stabilization of Proteins by Sucrose. *J Biol Chem* 256, 7193-7201.
46. Rozhkov, S.P. (1991). Stabilization of Protein by Sucrose as Revealed by the Spin-Label Method. *Biofizika+* 36, 571-576.
47. Ruan, K.C., Xu, C.H., Li, T.T., Li, J., Lange, R., and Balny, C. (2003). The thermodynamic analysis of protein stabilization by sucrose and glycerol against pressure-induced unfolding - The typical example of the 33-kDa protein from spinach photosystem II. *Eur J Biochem* 270, 1654-1661. 10.1046/j.1432-1033.2003.03485.x.
48. Jain, I., Minakhin, L., Mekler, V., Sitnik, V., Rubanova, N., Severinov, K., and Semenova, E. (2019). Defining the seed sequence of the Cas12b CRISPR-Cas effector complex. *Rna Biol* 16, 413-422. 10.1080/15476286.2018.1495492.
49. Gupta, E., Bajpai, M., and Choudhary, A. (2014). Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. *Asian J Transfus Sci* 8, 19-25. 10.4103/0973-6247.126683.
50. Madhvi, A., Hingane, S., Srivastav, R., Joshi, N., Subramani, C., Muthumohan, R., Khasa, R., Varshney, S., Kalia, M., Vratil, S., et al. (2017). A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound. *Sci Rep-Uk* 7. ARTN 5816 10.1038/s41598-017-04449-3.
51. Spearman, C.W., Dusheiko, G.M., Hellard, M., and Sonderup, M. (2019). Hepatitis C. *Lancet* 394, 1451-1466. 10.1016/S0140-6736(19)32320-7.
52. Zeuzem, S., Foster, G.R., Wang, S., Asatryan, A., Gane, E., Feld, J.J., Asselah, T., Bourliere, M., Ruane, P.J., Wedemeyer, H., et al. (2018). Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. *N Engl J Med* 378, 354-369. 10.1056/NEJMoa1702417.
53. Konerman, M.A., and Lok, A.S. (2014). Diagnostic challenges of hepatitis C. *JAMA* 311, 2536-2537. 10.1001/jama.2014.306.

54. Ishizaki, A., Bouscaillou, J., Luhmann, N., Liu, S., Chua, R., Walsh, N., Hess, S., Ivanova, E., Roberts, T., and Easterbrook, P. (2017). Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries. *BMC Infect Dis* 17, 696. 10.1186/s12879-017-2767-0.
55. Terrault, N.A. (2019). Hepatitis C elimination: challenges with under-diagnosis and under-treatment. *F1000Res* 8. 10.12688/f1000research.15892.1.
56. Hongjaisee, S., Doungjinda, N., Khamduang, W., Carraway, T.S., Wipasa, J., Debes, J.D., and Supparatpinyo, K. (2021). Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay. *Int J Infect Dis* 102, 440-445. 10.1016/j.ijid.2020.10.082.
57. Li, X.S., Wang, Y., Liu, Y.J., Yang, B., Wang, X., Wei, J., Lu, Z.Y., Zhang, Y.X., Wu, J., Huang, X.X., et al. (2018). Base editing with a Cpf1-cytidine deaminase fusion. *Nature Biotechnology* 36, 324-+. 10.1038/nbt.4102.
58. Wang, X., Ding, C.F., Yu, W.X., Wang, Y., He, S.T., Yang, B., Xiong, Y.C., Wei, J., Li, J.F., Liang, J.Y., et al. (2020). Cas12a Base Editors Induce Efficient and Specific Editing with Low DNA Damage Response. *Cell Rep* 31. ARTN 107723 10.1016/j.celrep.2020.107723.
59. Mirdita, M., Schutze, K., Moriwaki, Y., Heo, L., Ovchinnikov, S., and Steinegger, M. (2022). ColabFold: making protein folding accessible to all. *Nat Methods* 19, 679-+. 10.1038/s41592-022-01488-1.
60. Bienert, S., Waterhouse, A., de Beer, T.A.P., Tauriello, G., Studer, G., Bordoli, L., and Schwede, T. (2017). The SWISS-MODEL Repository-new features and functionality. *Nucleic Acids Research* 45, D313-D319. 10.1093/nar/gkw1132.
61. Zauli, D.A., Menezes, C.L., Oliveira, C.L., Mateo, E.C., and Ferreira, A.C. (2016). In-house quantitative real-time PCR for the diagnosis of hepatitis B virus and hepatitis C virus infections. *Braz J Microbiol* 47, 987-992. 10.1016/j.bjm.2016.07.008.

TABLE AND FIGURES LEGENDS




Figure 1. Structural prediction of BrCas12b. **(A)** Schematics of BrCas12b trans-cleavage. BrCas12b forms a binary complex with its sgRNA and binds to target dsDNA which activates its collateral ssDNA cleavage activity. **(B)** Predicted structures of BrCas12b derived from AlphaFold and SWISS-MODEL were spatially aligned with its most homologous Cas12b family member, BthCas12b (PDBID:5WTI)³⁹. The circled regions indicate misalignment between the two predicted models when aligned to the BthCas12b structure. **(C)** The fitness landscape of BrCas12b was calculated by DeepDDG. Each tile represents a computationally predicted change in the free energy ($\Delta\Delta G$) relative to the wild-type BrCas12b for the 20 amino acids. **(D)** Probability of preservation of function of three

residues (F208, L795, and T874) which are likely to increase the thermostability of the BrCas12b effector calculated by Hotspot Wizard 3.0.




Figure 2. Functional characterization of BrCas12b variants. (A) Change in melting temperature of BrCas12b variants compared to the wild-type effector (n = 4, two technical replicates examined over two independent experiments). Error bars represent mean \pm SEM. (B) Differential scanning fluorimetry plots in RFU comparing the wild-type BrCas12b for selected variants screened from (A) (n = 4, two technical replicates examined over two independent experiments). (C) Differential scanning fluorimetry plots in terms of derivative of RFU in (B). Global minima of the curve were determined to be the melting point of the protein (n = 4, two technical replicates examined over two independent experiments). (D) The trans-cleavage activity of BrCas12b variants was determined at increasing temperatures. Heat map represents the background corrected RFU at t = 15 min (n = 2 biological replicates). (E) and (F) Prediction accuracy in terms of thermostability for SWISS-MODEL and AlphaFold models (n = 4, two technical replicates examined over two independent experiments).




Figure 3. Engineered BrCas12b variants exhibit exceptional stability compared to wild-type BrCas12b. (A), (B), and (C) Time-dependent trans-cleavage activity at different temperatures for wild-type BrCas12b, FND (F208W/N524V/D868V) variant, and RFND (R160E/F208W/N524V/D868V) variant, respectively. The heat map represents background corrected RFU at t = 15 min (n = 2 biological replicates). (D), (E) and (F) Specificity testing of wild-type BrCas12b, FND variant, and RFND variant against mutated activators (n = 2 biological replicates). (G) Structural insights into the mechanism of enhanced stability of BrCas12b variants at amino acid positions 208 and 868. The top panels display the wild-type BrCas12b with F208 (left) and D868 (right) while the bottom panels depict the engineered eBrCas12b with W208 (left) and V868 (right).




Figure 4. RT-LAMP-coupled one-pot detection of BrCas12b variants. (A), (B), (C), and (D) One-pot detection of BrCas12b variants at 64°C, 65°C, 66°C, and 67°C, respectively (n=3 biological replicates). The variants: FND, FNT, FNLD, RFND,

FNPD, FNLDTA are abbreviated for F208W/N524V/D868V, F208W/N524V/T874S, F208W/N524V/L795I/D868V, R160E/F208W/N524V/D868V, F208W/N524V/P763C/D868V, F208W/N524V/L795I/D868V/T874S/A1015E, respectively. (E) Optimization of sucrose as an additive to the one-pot reaction at 67°C (n = 3 biological replicates). (F) One-pot detection reaction of BrCas12b variants with 200 mM sucrose at 67°C (n = 3 biological replicates). (G) and (H) PAM-dependent detection of RFND variant with and without RT-LAMP reaction.




Figure 5. Clinical validation of SPLENDID in Hepatitis C infected samples. (A) Schematic of the Hepatitis C RNA genome. Single-guide RNA was designed to target the 5' untranslated region (5' UTR) of the virus. (B) Detailed steps of the SPLENDID assay from patient sample extraction via a magnetic-based method to the one-pot testing. (C) Fluorescence measurements of 34 HCV-1, 4 HCV-2, and 2 HCV-3 as well as 40 healthy clinical samples from the SPLENDID assay. Different genotype Signal readouts were taken at t = 25 minutes. The reaction was run at 65°C, and this temperature was determined by screening the RT-LAMP reaction alone in the absence of CRISPR-eBrCas12b complex. (D) Summary of clinical validation SPLENDID in (D) in terms of sensitivity, specificity, and accuracy. (E) Receiver operating characteristic curve (ROC) of the assay at t = 25 minutes.

Supplementary Information

Engineering Highly Thermostable Cas12b via De Novo Structural Analyses for One-Pot Detection of Nucleic Acids

Long T. Nguyen^{1, †}, Santosh R. Rananaware^{1, †}, Lilia G. Yang^{1, †}, Nicolas C. Macaluso^{1, †, ††}, Julio E. Ocana-Ortiz², Katelyn S. Meister¹, Brianna L.M. Pizzano³, Luke Samuel W. Sandoval⁴, Raymond C. Hautamaki⁵, Zoe R. Fang⁵, Sara M. Joseph¹, Grace M. Shoemaker¹, Dylan R. Carman¹, Liwei Chang⁶, Noah R. Rakestraw⁷, Jon F. Zachary⁷, Sebastian Guerra⁸, Alberto Perez⁶, Piyush K. Jain^{1,9,10,*}

¹Department of Chemical Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville FL, USA

²Department of Chemical Engineering, University of Puerto Rico – Mayagüez, Puerto Rico, USA

³Department of Agricultural and Biological Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville FL, USA

⁴Department of Biology, College of Liberal Arts and Sciences, University of Florida, Gainesville, Florida, USA

⁵Department of Microbiology and Cell Science, College of Agricultural and Life Sciences, University of Florida, Gainesville, Florida, USA

⁶Department of Chemistry, College of Liberal Arts and Sciences, University of Florida, Gainesville, Florida, USA

⁷Department of Graduate Education, College of Medicine, University of Florida, Gainesville, Florida, USA

⁸Genetics Institute, College of Medicine, University of Florida, Gainesville, Florida, USA


⁹Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida, USA

¹⁰UF Health Cancer Center, University of Florida, Gainesville FL, USA

[†]These authors contributed equally

* Corresponding Author and Lead Contact: Jainp@ufl.edu

^{††}Present Address: Department of Chemical and Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University, Baltimore, Maryland, USA







Figure S1. Differential Scanning Fluorometric Measurements of All BrCas12b Variants Used in the Study, Related to Figure 2 . The curve at each temperature point represents the average of fluorescence over 4 replicates (n = 2 technical replicates per experiment over two experiments). The melting point (T_m) was determined as a global minimum of the derivative curve.






Figure S2. Time- and Temperature-dependent Trans-cleavage Activity of BrCas12b Variants Used in the Study, Related to Figure 2. The ribonucleoprotein complex and trans-cleavage reaction were incubated at 62°C, 65°C, 67°C, 68°C, and 70°C, respectively. Error bars represent mean \pm s.d., where n = 2 biological replicates.




Figure S3. BrCas12b Detection Optimization, Related to Figure 4. (A) Compatibility of BrCas12b-based detection reaction with commercially available RT-LAMP master mixes. (B) Additive optimization of the one-pot reaction with additives for the FNDLTA variant. Additives were mixed to a final concentration of 50 mM, and the reaction was incubated isothermally at 67°C. Each data point represents an average of triplicates ($n = 3$ biological replicates). (C) Effects of sucrose on the thermostability of wild-type BrCas12b and the thermally improved RFND variant. Melting temperatures were determined from differential scanning fluorimetry ($n = 2$ technical replicates per experiment over two experiments). The melting point (T_m) was identified as a global minimum of the derivative RFU curve with respect to temperature. (D), (E), and (F) SPLENDID assay using RFND variant in the presence and absence of sucrose at 64°C, 65°C, 66°C, respectively. The SARS-CoV-2 genomic RNA input was 25,000 copies. The fluorescence measurements were taken at $t = 30$ minutes. Each curve represents the average of fluorescence signals. The shaded area represents standard deviation, $n = 3$.




Figure S4. Correlation between In-house RT-qPCR and Clinically Validated Viral Loads for 80 HCV Patient Samples, Related to Figure 5.






Figure S5. Clinical Validation of SPLENDID and RT-LAMP Only in SARS-CoV-2 Infected Samples, Related to Figure 5. (A) and (B) Fluorescence measurements of 66 SARS-CoV-2 clinical samples (29 negative and 37 positive samples) from the RT-LAMP only or SPLENDID assay, respectively. Signal readouts were taken at $t = 30$ minutes. (C) and (D) Receiver operating characteristic curve (ROC) at $t = 30$ minutes of RT-LAMP only and SPLENDID assays, respectively. (E) Summary of clinical validation of SPLENDID and RT-LAMP only in terms of sensitivity, specificity, and accuracy.

Table S1. Sequences Used in the Study, Related to Figure 1-5.

RT-LAMP primers

Target	Name	Sequence
N gene of SARS-CoV-2	N_gene_F3	AACACAAGCTTTCGGCAG
	N_gene_B3	GAAATTTGGATCTTTGTCATCC
	N_gene_FIP	TGCGGCCAATGTTTGTAAATCAGCCAA GGAA ATTTTGGGGAC
	N_gene_BIP	CGCATTGGCATGGAAGTCACTTTGAT GGC ACCTGTGTAG
	N_gene_LF	TTCCTTGTCTGATTAGTTC
	N_gene_LB	ACCTTCGGGAACGTGGTT
5' UTR of Hepatitis C ¹	UTR_F3	CGGGAGAGCCATAGTGGT
	UTR_B3	WGGAWGTGTGCTCATGATGCACG
	UTR_FIP	AAATCTCCAGGCATTGAGCGTTTTTTCGGGAACCGGTGAGTAC
	UTR_BIP	CCGCRAGACYGCTAGCCGAGTTTTACCCTATCAGGCAGTACCAC
	UTR_LF	TCGTCCYGGCRATTCCGG
	UTR_LB	TAGTGTTGGGTCGCGAAAG

Single-guide RNAs

Target	Name	Sequence
N gene of SARS-CoV-2	Br_sgN_CoV2	GAAGGUGGUUAGCUACAGGCUGACCAGUGCAGUUGUGUCAUGUGCUACGG UGACCUAACACGUCACUCAGUCACAACGGCUAUCUAUAUUUCCACUAACCA AAGUUAGUGGAAAUGUAGAUGGUUAGCAC <u>CGAAGAACGCUGAAGCGCUG</u>
5' UTR of Hepatitis C	Br_sgUTR_HCV	GAAGGUGGUUAGCUACAGGCUGACCAGUGCAGUUGUGUCAUGUGCUACGG UGACCUAACACGUCACUCAGUCACAACGGCUAUCUAUAUUUCCACUAACCA AAGUUAGUGGAAAUGUAGAUGGUUAGCAC <u>UCCAAGAAAGGACCCGGUCG</u>

RT-qPCR primers²

Target	Name	Sequence
5' UTR of Hepatitis C	HCV_UTR_FOR	AGCGTCTAGCCATGGCGTT
	HCV_UTR_REV	GCAAGCACCTATCAGGCAGT
	HCV_UTR_Probe	/56-FAM/TCTGCGGAA/ZEN/CCGGTGAGT/3IABkFQ/

Reporters

Target	Name	Sequence
Universal	Reporter 1	/5HEX/TTTTTTTTT/3IABkFQ/
	Reporter 2	/5FAM/TTTTTTTTT/3IABkFQ/

Protein sequences

Name	Sequence
AapCas12b	MAVKSIVKLRLLDDMPEIRAGLWKLHKEVNAGVRYYTEWLSLLRQENLYR RSPNGDGEQCDKTAEECKAELLERLRARQVENGHRGPAGSDDELLQLA RQLYELLVPQAIGAKGDAQIARKFLSPLADKDAVGGGLGIAKAGNKPRWV RMREAGEPGWEEKEKAETRKSADRTADVLRLADFLGLKPLMRVYTDSE MSSVEWKPLRKGAQAVRTWDRDMFQQAIERMMSWESWNQRVGQEYAKL VEQKNRFEQKNFVGQEHVLVNLQQLQDMKEASPGLESKEQTAHYVTGR ALRGSDKVFEEKWGKLAPDAPFDLYDAEIKNVQRRNTRRFGSHDLFAKLAE

	<p>PEYQALWREDASFLTRYAVYNSILRKLNHAKMFATFTLPDATAHPIWTRFD KLGGNLHQYTLFNEFGERRHAIRFHKLLKVENGVAREVDDVTVPISMSE QLDNLLPRDPNEPIALYFRDYGAEQHFTGEFGGAKIQCRRDQLAHMHRRR GARDVYLVNSVRVQSQSEARGERRPPYA AVFRLVGDNHRAFVHFDKLSD YLAEHPPDDGKLGSEGLLSGLRVMSVDLGLRTSASISVFRVARKDELKPNS KGRVPFFFPKGNNDNLVAVHERSQLLKLPGETESKDLRAIREERQRTLRLQ RTQLAYLRLLVRCGSEDVGRRERSWAKLIEQPVDAAHMTDPDWREAFEN ELQKLKSLHGICSDKEWMDAVYESVRRVWRHMGKQVRDWRKDVRSGER PKIRGYAKDVVGGNSIEQIEYLERQYKFLKSWSFSGKVSGQVIRAEKGSRF AITLREHIDHAKEDRLKKLADRIIMEALGYVYALDERGKGKWWAKYPPCQLI LLEELSEYQFNDRPPSENNQLMQWSHRGVFQELINQAQVHDLLVGTMY AAFSSRFDARTGAPGIRCRRVPARCTQEHNPFPFWWLNKFVVEHTLDA CPLRADDLIPTGEGEIFVSPFSAEEGDFHQIHADLNAAQNLLQQLWSDFDI SQIRLRCDWGEVDGELVLIPRLTGKRTADSYSNKVFYTNVTGVTYYERERG KRRKVFAQEKLSEEEAELLVEADEAREKSVVLMRDPSGIINRGNWTRQK EFWSMVNQRIEGLVKQIRSRVPLQDSACENTGDI</p>
BrCas12b	<p>MPVRSFKVKLVTRSGDAEHMLQLRRGLWKTHEIVNQGIAYYMNKLALMR QEPYAGKSREVVRLELLHSLRAQQKRNNWTGDAGTDDEILNLSRRLYELL VPSAIGEKGDAQMLSRKFLSPLVDPNSEGGKGTAKSGRKPRWMKMREE GHPDWEAEREKDRAKKAADPTASILNDLEAFGLRPLFPLFTDEQKGIQWL PKQKRQFVRTFDRDMFQQALERMLSWESWNRRVAEEYQKLQAQRDELY AKYLADGGAWLEALQSFEKQREVELAEESFAAKSEYLITRRQIRGWKQVY EKWSQLPEHAAQEQFWQVADVQTSLPGAFGDPKVYQFLSQPEHHHIW RGYPNRLFHYSDYNGVRKKLQRARHDATFTLPDPVEHPLWIRFDARGGNI HDYEISQNGKQYQVTFSRLLWPENETWVERENVTAIGASQQLKRQIRLD GYADKKQKVRYRDYSSGIELTGVLGGAQIQFDRRHLRKASNRLADGETGP VYLVVVVDIEPFLAMRNGRLQTPIGQVLQVNTKDWPKVTGYKPAELISWIQ NSPLAVGTGVNTIEAGMRVMSVDLGQRSAAAVSIFVMRQKPAEQETKLF YPIAVTGLYAVHRRSLLLRLPGEKISDEIEQQRKIRAHARSLVRYQIRLLADV LRLHTRGTAEQRRAKLDELLATLQTKQELDQKLWQTELEKLFDYIHEPAER WQQALVAAHRTLEPVIGQAVRHWKSLRIDRKGLAGMSMWNIEELEETR KLLIAWSKHSRVPGEPNRLDKEETFAPQQLQHIQNVKDDRLKQMANLLVM TALGYKYDEAEKQWKEAYPACQMILFEDLSRYRFALDRPRENNRLMKW AHR SIPRLVYLQGELFGIQVGDVYSAYTSRFHAKTGAPGIRCHALKEEDLQ PNSYVVKQLIKDGFIREDDTGSCLKPGQIVPWSGGELFVTLADRSQSRLAVI HADINAAQNLLQKRFWQQNTEIFRVPCKVTTSGLIPAYDKMKKLFKGKYFA KINQTDTESEVYVWEHSAKMKGKTTTPADPAEEGVFDESLTDEMEELEDSDQ EGYKTLFRDPSGFFWSSDRWLPQKEFWFWVKRRIEKKLREQLQ</p>

Table S2. Genotype Specific Sensitivity for HCV-patient Samples, Related to Figure 5

Genotype	#samples	True Positive	False Negative	Sensitivity
GT1-(confirmed)	31	28	3	90%
GT1 (likely)	3	3	0	100%
GT1 (combined confirmed and likely)	34	31	3	91%
HCV-2 (confirmed)	4	2	2	50%
HCV-3 (confirmed)	2	0	2	0%

Table S3. Summary of Detection Platforms, Related to Figure 5.

	Target	Accuracy	Specificity	Sensitivity	Source
RT-qPCR	SARS-CoV-2	95.8	91.3	99.5	Banko <i>et al.</i> ³
	HCV	97%	100%	NA	Chen <i>et al.</i> ⁴ , Zhang <i>et al.</i> ⁵
STOP-Covid	SARS-CoV-2	95.8%	98.5%	93.1%	Joung <i>et al.</i> ⁶
SPADE	SARS-CoV-2	96.7%	99.4%	92.8%	Nguyen <i>et al.</i> ⁷
SHERLOCK	SARS-CoV-2	NA	100.0%	96.0%	Patchesung <i>et al.</i> ⁸
DETECTR	SARS-CoV-2	97.6%	100.0%	95.0%	Broughton <i>et al.</i> ⁹
ENHANCE	SARS-CoV-2	95.0%	96.8%	96.8%	Nguyen <i>et al.</i> ¹⁰
PMID: 35885430	HCV	97.0%	100.0%	96.0%	Kham-Kjing <i>et al.</i> ¹¹
SPLENDID	HCV	90.0% (overall)	97.5% (overall)	82.5% (overall)	This study
		94.6% (GT1)	97.5% (overall)	91.1% (GT1)	
	SARS-CoV-2	97.0%	100.0%	93.1%	

References

1. Hongjaisee, S., Doungjinda, N., Khamduang, W., Carraway, T.S., Wipasa, J., Debes, J.D., and Supparatpinyo, K. (2021). Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay. *Int J Infect Dis* 102, 440-445. 10.1016/j.ijid.2020.10.082.
2. Zauli, D.A., Menezes, C.L., Oliveira, C.L., Mateo, E.C., and Ferreira, A.C. (2016). In-house quantitative real-time PCR for the diagnosis of hepatitis B virus and hepatitis C virus infections. *Braz J Microbiol* 47, 987-992. 10.1016/j.bjm.2016.07.008.
3. Banko, A., Petrovic, G., Miljanovic, D., Loncar, A., Vukcevic, M., Despot, D., and Cirkovic, A. (2021). Comparison and Sensitivity Evaluation of Three Different Commercial Real-Time Quantitative PCR Kits for SARS-CoV-2 Detection. *Viruses-Basel* 13. ARTN 1321 10.3390/v13071321.
4. Chen, L.D., Li, W.L., Zhang, K., Zhang, R., Lu, T., Hao, M.J., Jia, T.T., Sun, Y., Lin, G.G., Wang, L.N., and Li, J.M. (2016). Hepatitis C Virus RNA Real-Time Quantitative RT-PCR Method Based on a New Primer Design Strategy. *J Mol Diagn* 18, 84-91. 10.1016/j.jmoldx.2015.07.009.
5. Zhang, E.Z., Bartels, D.J., Frantz, J.D., Seepersaud, S., Lippke, J.A., Shames, B., Zhou, Y., Lin, C., Kwong, A., and Kieffer, T.L. (2013). Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples. *Virol J* 10. ArtN 53 10.1186/1743-422x-10-53.
6. Joung, J., Ladha, A., Saito, M., Kim, N.G., Woolley, A.E., Segel, M., Barretto, R.P.J., Ranu, A., Macrae, R.K., Faure, G., et al. (2020). Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. *N Engl J Med* 383, 1492-1494. 10.1056/NEJMc2026172.
7. Nguyen, L.T., Macaluso, N.C., Pizzano, B.L.M., Cash, M.N., Spacek, J., Karasek, J., Miller, M.R., Lednicky, J.A., Dinglasan, R.R., Salemi, M., and Jain, P.K. (2022). A thermostable Cas12b from *Brevibacillus* leverages one-pot discrimination of SARS-CoV-2 variants of concern. *Ebiomedicine* 77. ARTN 103926 10.1016/j.ebiom.2022.103926.
8. Patchsung, M., Jantarug, K., Pattama, A., Aphicho, K., Suraritdechachai, S., Meesawat, P., Sappakhaw, K., Leelahakorn, N., Ruenkam, T., Wongsatit, T., et al. (2020). Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. *Nat Biomed Eng* 4, 1140-1149. 10.1038/s41551-020-00603-x.
9. Broughton, J.P., Deng, X., Yu, G., Fasching, C.L., Servellita, V., Singh, J., Miao, X., Streithorst, J.A., Granados, A., Sotomayor-Gonzalez, A., et al. (2020). CRISPR-Cas12-based detection of SARS-CoV-2. *Nat Biotechnol* 38, 870-874. 10.1038/s41587-020-0513-4.
10. Nguyen, L.T., Rananaware, S.R., Pizzano, B.L.M., Stone, B.T., and Jain, P.K. (2022). Clinical validation of engineered CRISPR/Cas12a for rapid SARS-CoV-2 detection. *Commun Med (Lond)* 2, 7. 10.1038/s43856-021-00066-4.
11. Kham-Kjing, N., Ngo-Giang-Huong, N., Tragoolpua, K., Khamduang, W., and Hongjaisee, S. (2022). Highly Specific and Rapid Detection of Hepatitis C Virus Using RT-LAMP-Coupled CRISPR-Cas12 Assay. *Diagnostics (Basel)* 12. 10.3390/diagnostics12071524.